Investor Relations

Overview

Minimum 15 minutes delayed. Source: LSEG

Corporate Profile

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses. For more information visit www.Aligos.com or follow us on LinkedIn.

View All

SEC Filings

Filing Date	Form
Nov 18, 2024	EFFECT
Nov 14, 2024	SC 13G/A

View All

About
Science
- Pipeline
- Posters & Presentations
Patients
News & Media
- Press Releases
- Presentations & Events
Investors
Careers

News Releases

Events

SEC Filings